Detalles de la búsqueda
1.
Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
Lancet
; 394(10208): 1519-1529, 2019 10 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31542292
2.
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.
N Engl J Med
; 374(16): 1521-32, 2016 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-27043774
3.
A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM.
Diabetes Obes Metab
; 21(10): 2240-2247, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31144427
4.
Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.
ESC Heart Fail
; 10(1): 80-89, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36125177
5.
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Lancet
; 375(9721): 1173-81, 2010 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-20170948
6.
Efficacy and safety of valsartan in children aged 1-5 years with hypertension, with or without chronic kidney disease: a randomized, double-blind study followed by open-label phase.
Curr Med Res Opin
; 37(12): 2113-2122, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34543161
7.
Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial.
Eur J Heart Fail
; 20(1): 136-147, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28948656
8.
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Am J Hypertens
; 20(1): 11-20, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17198906
9.
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.
Circulation
; 111(8): 1012-8, 2005 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15723979
10.
Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFT.
Eur J Heart Fail
; 8(5): 502-8, 2006 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16386464
11.
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Circulation
; 108(11): 1306-9, 2003 Sep 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-12939207
12.
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
Circulation
; 107(9): 1278-83, 2003 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-12628948
13.
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Circulation
; 106(19): 2454-8, 2002 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-12417542
14.
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
J Am Coll Cardiol
; 40(5): 970-5, 2002 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-12225725
15.
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics.
Eur J Heart Fail
; 17(10): 1075-83, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26511146
16.
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
Eur J Heart Fail
; 6(7): 937-45, 2004 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-15556056
Resultados
1 -
16
de 16
1
Próxima >
>>